Your browser doesn't support javascript.
SARS-CoV-2 Antiviral Therapy.
Tao, Kaiming; Tzou, Philip L; Nouhin, Janin; Bonilla, Hector; Jagannathan, Prasanna; Shafer, Robert W.
  • Tao K; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
  • Tzou PL; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
  • Nouhin J; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
  • Bonilla H; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
  • Jagannathan P; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
  • Shafer RW; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
Clin Microbiol Rev ; 34(4): e0010921, 2021 12 15.
Article in English | MEDLINE | ID: covidwho-1575724
ABSTRACT
The development of effective antiviral therapy for COVID-19 is critical for those awaiting vaccination, as well as for those who do not respond robustly to vaccination. This review summarizes 1 year of progress in the race to develop antiviral therapies for COVID-19, including research spanning preclinical and clinical drug development efforts, with an emphasis on antiviral compounds that are in clinical development or that are high priorities for clinical development. The review is divided into sections on compounds that inhibit SARS-CoV-2 enzymes, including its polymerase and proteases; compounds that inhibit virus entry, including monoclonal antibodies; interferons; and repurposed drugs that inhibit host processes required for SARS-CoV-2 replication. The review concludes with a summary of the lessons to be learned from SARS-CoV-2 drug development efforts and the challenges to continued progress.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Clin Microbiol Rev Journal subject: Microbiology Year: 2021 Document Type: Article Affiliation country: CMR.00109-21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Clin Microbiol Rev Journal subject: Microbiology Year: 2021 Document Type: Article Affiliation country: CMR.00109-21